Sodium oxybate in the treatment of binge eating disorder: An open‐label, prospective study

McElroy, Susan L.; Guerdjikova, Anna I.; Winstanley, Erin L.; O’Melia, Anne; Mori, Nicole; Keck, Paul E.; Hudson, James I.

doi:10.1002/eat.20798

Cited by 29 publications

(16 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, individual patients did experience modest losses in weight with the overall group profile indicative of some benefit relative to placebo. Such findings are consistent with an open-label trial in humans (Arima and Oiso, 2010), and research in rats (Patel and Ebenezer 2010), in which baclofen has been reported to reduce body weight, as well as an open-label trial in which sodium oxybate, which also acts as a GABA-B agonist, reduced binge eating and body weight (McElroy et al, 2011).…”

Section: Discussionsupporting

confidence: 67%

See 1 more Smart Citation

Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study

Corwin¹,

Boan

Peters

et al. 2012

Behavioural Pharmacology

View full text Add to dashboard Cite

Baclofen has shown promise in treating substance use disorders and also reduced binge frequency in an open-label trial. This placebo-controlled, double-blind, crossover study further assessed the effects of baclofen on binge eating. Twelve individuals who self-reported binge eating completed the study. Data were collected during a run-in period (no drug or placebo), placebo phase (48 days), and baclofen phase (titrated up to 60 mg daily or the maximum tolerated dose, 48 days). All the participants were exposed to all conditions. Participants completed a binge diary daily, and the Binge Eating Scale (BES), Food Craving Inventory-II (FCI-II), and Hospital Anxiety and Depression Scale (HADS) at regular intervals throughout the study. Baclofen significantly reduced binge frequency relative to placebo and run-in (P<0.05). This confirms results from the previous open-label trial. Baclofen also produced slight, but significant, increases in depression symptomatology as assessed by the HADS. Binge severity (BES scores) and craving (FCI-II scores) were significantly reduced during placebo and baclofen phases, that is both measures exhibited significant placebo effects. Tiredness, fatigue, and upset stomach were the most commonly reported side-effects. These results indicate that baclofen may be a useful treatment for binge eating in some patients.

show abstract

Section: Discussionsupporting

confidence: 67%

“…In addition to the open-label baclofen trial, results are also consistent with an open-label trial in which sodium oxybate reduced binge frequency (McElroy et al, 2011).…”

Section: Discussionmentioning

confidence: 68%

Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study

Corwin¹,

Boan

Peters

et al. 2012

Behavioural Pharmacology

View full text Add to dashboard Cite

show abstract

“…Reports of weight loss with GHB are less common, although popular use of the drug by body builders during the 1990s was predicated on its ability to release growth hormone, leading to increased lean muscular mass and diminished body fat (Fuller et al 2004). Indeed, patients treated chronically with GHB for narcolepsy show loss of body weight over time (Husain et al 2009) and a recent open-label trial found GHB to be efficacious in promoting appetite control and body weight loss in people suffering from binge eating disorders (McElroy et al 2010). The present study is, to our knowledge, the first report of chronic GHB-induced body weight loss in rats and it is interesting to note that this effect tended to persist for several weeks following cessation of GHB treatment.…”

Section: Discussionmentioning

confidence: 99%

Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination

et al. 2010

View full text Add to dashboard Cite

show abstract

“…These associations were not related to the presence of other sleep disorders nor to current pharmacological treatment, although we cannot rule out an effect of the NC medications. Previous studies, however, have shown that modafinil, venlafaxine, and sodium oxybate decrease food intake/ craving, [38][39][40] suggesting that these treatments could have mitigated these abnormal nocturnal behaviors.…”

Section: Demographic Features Sleep Comorbidity and Psychological Tmentioning

confidence: 95%

Narcolepsy with Cataplexy Associated with Nocturnal Compulsive Behaviors: A Case-Control Study

Palaia

Poli

Pizza

et al. 2011

Sleep

View full text Add to dashboard Cite

INTRODUCTIONNarcolepsy with cataplexy (NC) is a central nervous system hypersomnia, characterized by excessive daytime sleepiness (EDS), cataplexy (transient loss of muscle tone triggered by emotions), sleep paralysis, hypnagogic hallucinations, and disrupted nocturnal sleep. 1 It is caused by the selective loss of hypothalamic neurons 2 producing hypocretin-1 and 2 (or orexin-A and B), 3,4 two related peptides involved in regulation of sleep-wake transition, energy homeostasis, feeding behavior, and reward systems.5 Accordingly, low/undetectable cerebrospinal (CSF) hypocretin-1 (hrct-1) is observed in almost all cases of NC.Sleep-related eating disorder (SRED) is a NREM parasomnia, characterized by recurrent episodes of involuntary eating and drinking during arousals from the main sleep period. It involves nocturnal consumption of food or toxic substances, dis- [Bdi]). Measurements and Results: NC patients showed a higher prevalence of sRed (32% vs 3%, P = 0.00001), Ns (21% vs 0%, P = 0.00006), and Rls (18% vs 5%, P = 0.013) than controls. Moreover, NC patients presented more frequently with an eating-related pathological profile on the edi-2 (80% vs 46%, P = 0.00006) and had a higher prevalence of depressed mood on the Bdi (41% vs 18%, P = 0.004). in comparison to patients without sRed, NC patients with sRed were more frequently women (71% vs 39%, P = 0.013), had higher "bulimic" (29% vs 2%, P = 0.004) and "social insecurity" (48% vs 18%, P = 0.013) traits on the edi-2, had higher obsessive-compulsiveness on the MoCi (29% vs 4%, P = 0.009), and were more depressed on the Bdi (67% vs 29%, P = 0.005). NC patients with Ns showed more frequent pathological profiles on the edi-2 (100% vs 75%, P = 0.035), including the "bulimic" (29% vs 6%, P = 0.015), "perfectionism" (43% vs 14%, P = 0.016), and "social insecurity" (50% vs 22, P = 0.035) profiles. Conclusion: our study shows a strong association of the compulsive nocturnal behaviors sRed and Ns with adult NC. NARCOLEPSY WITH CATAPLEXY AND NOCTURNAL COMPULSIVE BEHAVIORS

show abstract

Sodium oxybate in the treatment of binge eating disorder: An open‐label, prospective study

Abstract: In this open-label trial, sodium oxybate was effective in binge eating disorder, but associated with high a discontinuation rate.

Cited by 29 publications

References 50 publications

Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study

Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study

Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination

Narcolepsy with Cataplexy Associated with Nocturnal Compulsive Behaviors: A Case-Control Study

Contact Info

Product

Resources

About